OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bewi ASA
OSE:BEWI
|
NO |
|
Magnite Inc
NASDAQ:MGNI
|
US |
OSE Immunotherapeutics SA
Retained Earnings
OSE Immunotherapeutics SA
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Retained Earnings
-€31.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-18%
|
|
|
Valneva SE
PAR:VLA
|
Retained Earnings
-€592.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-18%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Retained Earnings
-€475.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-21%
|
|
|
Inventiva SA
PAR:IVA
|
Retained Earnings
-€387.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Retained Earnings
-$214.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-10%
|
|
|
Abivax SA
PAR:ABVX
|
Retained Earnings
-€438.9m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-35%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Retained Earnings?
Retained Earnings
-31.2m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Retained Earnings amounts to -31.2m EUR.
What is OSE Immunotherapeutics SA's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-18%
The average annual Retained Earnings growth rates for OSE Immunotherapeutics SA have been -12% over the past three years , and -18% over the past ten years .
